Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Use of Immersive Virtual Reality to Train the Multisensory Processing Capacities of Children Aged 8 to 16 Years-old With an Autism Spectrum Disorder: Single-center Randomized Pilot Study in Parallel Groups - SEVIRE. (Sensory Virtual Reality)

NCT05171244 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2022-03-03
Last updated
2026-06-11

Condition(s) studied

Autism Spectrum Disorder

Investigational drug(s) / intervention(s)

virtual reality trainingusual care

virtual reality training: training of multisensory processing capacities in virtual reality in addition to usual program of interventions in usual care

usual care: usual program of interventions in usual care

Study summary

Autism Spectrum Disorder (ASD) is defined as a neurodevelopmental disorder that affects the functioning and development of social communication (DSM5 - 2013). ASD causes particularities in sensory treatments (auditory, visual), qualified as uni-modal. Added to this, there is difficulties to deal with prevailing stimuli of the environment (pluri-modal) ; parents report the discomfort of their child in this situation with "noisy" behavioral manifestations. Therapeutic social skills programs most often address the subject's lack of adjustment to their environment through understanding social rules and codes and cognitive treatment of situations.

Thus, in order to relieve the sensory modulation disorders which can be the cause of social adjustment difficulties, it's propose to exercise the sensory habituation of children with ASD thanks to virtual reality scenarios restored in 3D immersion booth (the CAVE). The child will be exposed to multimodal stimulation during immersion sessions reproducing the conditions of an ecological environment. A therapist will accompany the child in the CAVE throughout the session.

The investigators hypothesize that regular and repeated exposure to a simulated environment in the CAVE can improve multisensory treatment capacities and have a beneficial effect on the autonomy of children and adolescents with ASD in everyday situations.

Eligibility

Sex
ALL
Min age
8 Years
Max age
16 Years
Healthy volunteers
No
Inclusion Criteria: * Child / adolescent aged 8 to 16 years, diagnosed with ASD (DSM-5, ADOS, ADI-R criteria). * Without intellectual delay (QNV\> 70, WISC-IV or V, WAIS-III or IV). * Benefiting from a treatment program at the University Center for Child Psychiatry (CHRU Bretonneau-Tours). * Schooled in the ordinary school context (primary school, middle school, high school, ULIS). * Having expressed their agreement to participate in the study. * Whose parents or legal representatives have signed written consent. * Whose parents or legal representatives are affiliated or beneficiaries of a social security scheme. Exclusion Criteria: * Neuromotor disorders. * Uncorrected visual disorders. * Hearing impairment. * Known epilepsy. * Anxiety syndromes identified. * Hyper ADD / H type activity. * Treatment with methylphenidate. - Rare genetic syndrome.

Primary outcome measure(s)

  • Vineland Adaptive Behavior Scales II (VABS II) score — Baseline, week 15 (after training), 6 months after training
    Behavioral scale VABS II is a test for assessing autonomy of child/adolescent in everyday life. From 0 to 108, higher is the score, more independent the person is in the rated field.

Trial sites (2)

FacilityCityRegionStatus
Le Centre universitaire de pédopsychiatrie Tours Tours Recruiting
Pedopsychiatry, University Hospital, Tours Tours France Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05171244 on ClinicalTrials.gov ↗ ← All trials in France